Adicet Bio (ACET) Stock Forecast, Price Target & Predictions
ACET Stock Forecast
Adicet Bio stock forecast is as follows: an average price target of $32.50 (represents a 2081.21% upside from ACET’s last price of $1.49) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
ACET Price Target
The average price target for Adicet Bio (ACET) is $32.50 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $38.00 to $27.00. This represents a potential 2081.21% upside from ACET's last price of $1.49.
ACET Analyst Ratings
According to 6 Wall Street analysts, Adicet Bio's rating consensus is 'Buy'. The analyst rating breakdown for ACET stock is 0 'Strong Buy' (0.00%), 3 'Buy' (50.00%), 3 'Hold' (50.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Adicet Bio Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Dec 12, 2022 | - | H.C. Wainwright | $38.00 | $17.27 | 120.03% | 2450.34% |
| Mar 04, 2022 | Kelly Shi | Jefferies | $27.00 | $12.56 | 114.97% | 1712.08% |
The latest Adicet Bio stock forecast, released on Dec 12, 2022 by H.C. Wainwright company, set a price target of $38.00, which represents a 120.03% increase from the stock price at the time of the forecast ($17.27), and a 2450.34% increase from ACET last price ($1.49).
Adicet Bio Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $1.49 | $1.49 | $1.49 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Adicet Bio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Adicet Bio's last price of $1.49. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 11, 2024 | Piper Sandler | - | Neutral | Downgrade |
| Sep 11, 2024 | Canaccord Genuity | Buy | Buy | Hold |
| Sep 11, 2024 | H.C. Wainwright | - | Neutral | Downgrade |
| Nov 09, 2023 | Wedbush | Outperform | Outperform | Hold |
| Jun 27, 2023 | JMP Securities | - | Market Perform | Downgrade |
| Mar 04, 2022 | Jefferies | - | Buy | Initialise |
Adicet Bio's last stock rating was published by Piper Sandler on Sep 11, 2024. The company Downgrade its ACET rating from "null" to "Neutral".
Adicet Bio Financial Forecast
Adicet Bio Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Mar 20 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | $-24.99M | - | - | $24.99M | $6.02M | $3.43M | $4.81M | $-3.98M | $2.00M | $-7.05M |
| Avg Forecast | - | - | - | - | $625.00K | $625.00K | $625.00K | $625.00K | $1.11M | $12.67M | $4.42M | $13.00M | $333.33K | $1.11M | $14.39M | $4.16M | $2.69M | $2.00M | $1.17M | $2.59M | $-5.17M |
| High Forecast | - | - | - | - | $625.00K | $625.00K | $625.00K | $625.00K | $1.11M | $12.67M | $4.42M | $13.00M | $333.33K | $1.11M | $14.39M | $4.16M | $2.69M | $2.00M | $1.17M | $3.10M | $-4.14M |
| Low Forecast | - | - | - | - | $625.00K | $625.00K | $625.00K | $625.00K | $1.11M | $12.67M | $4.42M | $13.00M | $333.33K | $1.11M | $14.39M | $4.16M | $2.69M | $2.00M | $1.17M | $2.07M | $-6.21M |
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 7 | 7 | 7 | 7 | 15 | 18 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | -1.92% | - | - | 1.74% | 1.45% | 1.28% | 2.41% | -3.41% | 0.77% | 1.36% |
Adicet Bio's average Quarter revenue forecast for Mar 23 based on 2 analysts is $4.42M, with a low forecast of $4.42M, and a high forecast of $4.42M. ACET's average Quarter revenue forecast represents a -117.70% decrease compared to the company's last Quarter revenue of $-24.99M (Dec 22).
Adicet Bio EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Mar 20 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 7 | 7 | 7 | 7 | 15 | 18 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-34.89M | $-30.86M | $-29.85M | $-21.22M | $-22.11M | $5.03M | $-16.15M | $-13.56M | $-10.42M | $-20.99M | $-6.85M | $-14.78M |
| Avg Forecast | - | - | - | - | $-375.00K | $-375.00K | $-375.00K | $-375.00K | $-666.67K | $-7.60M | $-2.65M | $-7.80M | $-14.45M | $-668.57K | $11.47M | $-2.50M | $-1.61M | $-1.20M | $-16.01M | $-8.86M | $-10.85M |
| High Forecast | - | - | - | - | $-375.00K | $-375.00K | $-375.00K | $-375.00K | $-666.67K | $-7.60M | $-2.65M | $-7.80M | $-11.56M | $-668.57K | $13.77M | $-2.50M | $-1.61M | $-1.20M | $-12.81M | $-7.09M | $-8.68M |
| Low Forecast | - | - | - | - | $-375.00K | $-375.00K | $-375.00K | $-375.00K | $-666.67K | $-7.60M | $-2.65M | $-7.80M | $-17.34M | $-668.57K | $9.18M | $-2.50M | $-1.61M | $-1.20M | $-19.21M | $-10.63M | $-13.02M |
| Surprise % | - | - | - | - | - | - | - | - | - | 4.59% | 11.63% | 3.83% | 1.47% | 33.08% | 0.44% | 6.46% | 8.41% | 8.68% | 1.31% | 0.77% | 1.36% |
1 analysts predict ACET's average Quarter EBITDA for Jun 22 to be $-668.57K, with a high of $-668.57K and a low of $-668.57K. This is -113.30% lower than Adicet Bio's previous annual EBITDA (Mar 22) of $5.03M.
Adicet Bio Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Mar 20 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 7 | 7 | 7 | 7 | 15 | 18 |
| Net Income | - | - | - | - | - | - | - | - | - | $-32.40M | $-29.63M | $-28.10M | $-21.01M | $-22.37M | $4.62M | $-15.81M | $-14.01M | $-10.85M | $-21.32M | $-4.49M | $-14.78M |
| Avg Forecast | $-29.30M | $-29.61M | $-28.40M | $-32.63M | $-31.95M | $-31.04M | $-32.98M | $-63.14M | $-66.80M | $-41.69M | $-52.23M | $-25.38M | $-14.93M | $-41.24M | $10.62M | $-38.18M | $-38.97M | $-47.26M | $-16.26M | $-5.80M | $-10.85M |
| High Forecast | $-29.30M | $-29.61M | $-28.40M | $-32.63M | $-31.95M | $-24.65M | $-32.98M | $-39.46M | $-66.80M | $-41.69M | $-52.23M | $-25.38M | $-11.94M | $-41.24M | $12.75M | $-38.18M | $-38.97M | $-47.26M | $-13.01M | $-4.64M | $-8.68M |
| Low Forecast | $-29.30M | $-29.61M | $-28.40M | $-32.63M | $-31.95M | $-33.78M | $-32.98M | $-77.17M | $-66.80M | $-41.69M | $-52.23M | $-25.38M | $-17.91M | $-41.24M | $8.50M | $-38.18M | $-38.97M | $-47.26M | $-19.51M | $-6.96M | $-13.02M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.78% | 0.57% | 1.11% | 1.41% | 0.54% | 0.43% | 0.41% | 0.36% | 0.23% | 1.31% | 0.77% | 1.36% |
Adicet Bio's average Quarter net income forecast for Jun 22 is $-41.24M, with a range of $-41.24M to $-41.24M. ACET's average Quarter net income forecast represents a -992.97% decrease compared to the company's last Quarter net income of $4.62M (Mar 22).
Adicet Bio SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Mar 20 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 7 | 7 | 7 | 7 | 15 | 18 |
| SG&A | - | - | - | - | - | - | - | - | - | $6.53M | $6.57M | $6.55M | $6.42M | $6.53M | $6.80M | $6.35M | $5.21M | $5.03M | $5.63M | $2.52M | $1.85M |
| Avg Forecast | - | - | - | - | $1.79M | $1.79M | $1.79M | $1.79M | $3.19M | $36.34M | $12.69M | $37.30M | $956.19K | $3.20M | $41.28M | $11.95M | $7.71M | $5.74M | $3.35M | $7.42M | $-14.84M |
| High Forecast | - | - | - | - | $1.79M | $1.79M | $1.79M | $1.79M | $3.19M | $36.34M | $12.69M | $37.30M | $956.19K | $3.20M | $41.28M | $11.95M | $7.71M | $5.74M | $3.35M | $8.90M | $-11.87M |
| Low Forecast | - | - | - | - | $1.79M | $1.79M | $1.79M | $1.79M | $3.19M | $36.34M | $12.69M | $37.30M | $956.19K | $3.20M | $41.28M | $11.95M | $7.71M | $5.74M | $3.35M | $5.93M | $-17.81M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.18% | 0.52% | 0.18% | 6.71% | 2.04% | 0.16% | 0.53% | 0.68% | 0.88% | 1.68% | 0.34% | -0.12% |
Adicet Bio's average Quarter SG&A projection for Sep 23 is $3.19M, based on 2 Wall Street analysts, with a range of $3.19M to $3.19M. The forecast indicates a -51.17% fall compared to ACET last annual SG&A of $6.53M (Jun 23).
Adicet Bio EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Mar 20 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 7 | 7 | 7 | 7 | 15 | 18 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.00 | $-0.69 | $-0.67 | $-0.50 | $-0.56 | $0.12 | $-0.47 | $-0.44 | $-0.34 | $-0.82 | $-0.23 | $-0.75 |
| Avg Forecast | $-0.32 | $-0.33 | $-0.31 | $-0.36 | $-0.35 | $-0.34 | $-0.36 | $-0.70 | $-0.74 | $-0.46 | $-0.58 | $-0.28 | $-0.53 | $-0.46 | $-0.18 | $-0.42 | $-0.43 | $-0.52 | $-0.48 | $-2.35 | $-3.76 |
| High Forecast | $-0.32 | $-0.33 | $-0.31 | $-0.36 | $-0.35 | $-0.27 | $-0.36 | $-0.44 | $-0.74 | $-0.46 | $-0.58 | $-0.28 | $-0.53 | $-0.46 | $-0.18 | $-0.42 | $-0.43 | $-0.52 | $-0.48 | $-2.35 | $-3.76 |
| Low Forecast | $-0.32 | $-0.33 | $-0.31 | $-0.36 | $-0.35 | $-0.37 | $-0.36 | $-0.85 | $-0.74 | $-0.46 | $-0.58 | $-0.28 | $-0.53 | $-0.46 | $-0.18 | $-0.42 | $-0.43 | $-0.52 | $-0.48 | $-2.35 | $-3.76 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.00% | 1.20% | 2.39% | 0.94% | 1.23% | -0.66% | 1.12% | 1.02% | 0.65% | 1.71% | 0.10% | 0.20% |
According to 1 Wall Street analysts, Adicet Bio's projected average Quarter EPS for Jun 22 is $-0.46, with a low estimate of $-0.46 and a high estimate of $-0.46. This represents a -479.17% decrease compared to ACET previous annual EPS of $0.12 (Mar 22).
Adicet Bio Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ACET | Adicet Bio | $1.49 | $32.50 | 2081.21% | Buy |
| AVTE | Aerovate Therapeutics | $1.90 | $13.00 | 584.21% | Hold |
| VOR | Vor Biopharma | $1.05 | $6.00 | 471.43% | Buy |
| NKTX | Nkarta | $5.71 | $21.60 | 278.28% | Buy |
| PLRX | Pliant Therapeutics | $12.00 | $39.71 | 230.92% | Buy |
| FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
| ANEB | Anebulo Pharmaceuticals | $2.08 | $6.00 | 188.46% | Buy |
| BCYC | Bicycle Therapeutics | $27.02 | $70.50 | 160.92% | Buy |
| EWTX | Edgewise Therapeutics | $18.83 | $48.00 | 154.91% | Buy |
| ACRV | Acrivon Therapeutics | $8.91 | $21.50 | 141.30% | Buy |
| STOK | Stoke Therapeutics | $14.47 | $33.75 | 133.24% | Buy |
| IGMS | IGM Biosciences | $12.30 | $25.00 | 103.25% | Buy |
| KROS | Keros Therapeutics | $56.98 | $105.00 | 84.28% | Buy |
| CGEM | Cullinan Oncology | $17.95 | $32.00 | 78.27% | Buy |
| AGIO | Agios Pharmaceuticals | $46.69 | $47.50 | 1.73% | Buy |
| AADI | Aadi Bioscience | $1.80 | $1.63 | -9.44% | Hold |
ACET Forecast FAQ
Is Adicet Bio a good buy?
Yes, according to 6 Wall Street analysts, Adicet Bio (ACET) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 50.00% of ACET's total ratings.
What is ACET's price target?
Adicet Bio (ACET) average price target is $32.5 with a range of $27 to $38, implying a 2081.21% from its last price of $1.49. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Adicet Bio stock go up soon?
According to Wall Street analysts' prediction for ACET stock, the company can go up by 2081.21% (from the last price of $1.49 to the average price target of $32.5), up by 2450.34% based on the highest stock price target, and up by 1712.08% based on the lowest stock price target.
Can Adicet Bio stock reach $2?
ACET's average twelve months analyst stock price target of $32.5 supports the claim that Adicet Bio can reach $2 in the near future.
What are Adicet Bio's analysts' financial forecasts?
Adicet Bio's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $1.88M (high $1.88M, low $1.88M), average EBITDA is $-1.125M (high $-1.125M, low $-1.125M), average net income is $-95.968M (high $-89.578M, low $-98.707M), average SG&A $5.38M (high $5.38M, low $5.38M), and average EPS is $-1.059 (high $-0.988, low $-1.089). ACET's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-120M (high $-120M, low $-120M), average SG&A $0 (high $0, low $0), and average EPS is $-1.323 (high $-1.323, low $-1.323).
Did the ACET's actual financial results beat the analysts' financial forecasts?
Based on Adicet Bio's last annual report (Dec 2022), the company's revenue was $24.99M, which missed the average analysts forecast of $28.84M by -13.35%. Apple's EBITDA was $-69.71M, beating the average prediction of $-11.446M by 509.03%. The company's net income was $-67.029M, missing the average estimation of $-70.921M by -5.49%. Apple's SG&A was $26.3M, missing the average forecast of $82.73M by -68.22%. Lastly, the company's EPS was $-1.63, beating the average prediction of $-1.449 by 12.51%. In terms of the last quarterly report (Dec 2022), Adicet Bio's revenue was $-24.99M, missing the average analysts' forecast of $13M by -292.21%. The company's EBITDA was $-29.849M, beating the average prediction of $-7.801M by 282.64%. Adicet Bio's net income was $-28.103M, beating the average estimation of $-25.377M by 10.74%. The company's SG&A was $6.55M, missing the average forecast of $37.3M by -82.44%. Lastly, the company's EPS was $-0.67, beating the average prediction of $-0.28 by 139.29%